IGF2BP1 and cancer: As oncogenes of AML, METTL3 (Vu et al., 2017), METTL14 (Weng et al., 2018), WTAP (Bansal et al., 2014), FTO (Li et al., 2017), YTHDF2 (Li Z. et al., 2018), and IGF2BP1 (Zhou et al., 2017) participate in tumor processes through a variety of pathways, including the promotion of the growth of cancer cells and inhibition of apoptosis.